DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 📋 Regulatory Action / Label Change
The approval adds an mRNA option to seasonal influenza vaccination for adults aged 50 and older. Moderna expects US availability during the 2026–2027 respiratory virus season.
Professional Impact
- Full approval for adults 50 to 64 followed a randomized trial involving more than 40,000 participants.
- Adults 65 and older received accelerated approval based on immune-response comparisons with high-dose vaccination.
- Confirmatory evidence remains required to establish clinical effectiveness in the older population.
- The new vaccine expands choice but does not replace established influenza vaccine options.
Action Items
- Monitor product availability, distribution timing, and formulary coverage.
- Review final federal recommendations before incorporating mFLUSIVA into vaccination workflows.
- Distinguish full approval from accelerated approval during patient counseling.
- Document allergy history, immunocompromising conditions, and previous vaccine-associated Guillain-Barré syndrome.
